COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

1 - 172 . (canceled)

173 . A method for treating an ocular condition, comprising administering to a subject in need thereof a therapeutically-effective amount of a HPTP-β inhibitor; and

a therapeutically-effective amount of an anti-VEGF agent, wherein the anti-VEGF agent is ranibizumab, bevacizumab, or aflibercept.

174 . The method of claim 173 , wherein the HPTP-β inhibitor has the formula:

wherein R is a substituted or unsubstituted thiazolyl unit having the formula:

R 2 , R 3 , and R 4 are each independently:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkenyl;

iv) substituted or unsubstituted C 2 -C 6 linear or branched alkynyl;

v) substituted or unsubstituted C 6 or C 10 aryl;

vi) substituted or unsubstituted C 1 -C 9 heteroaryl;

vii) substituted or unsubstituted C 1 -C 9 heterocyclic; or

viii) R 2 and R 3 taken together to form a saturated or unsaturated ring having from 5 to 7 atoms;

wherein from 1 to 3 atoms can optionally be oxygen, nitrogen, or sulfur;

Z is a unit having the formula:

-(L) n -R 1

R 1 is:

i) hydrogen;

ii) hydroxyl;

iii) amino;

iv) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

v) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkoxy;

vi) substituted or unsubstituted C 6 or C 10 aryl;

vii) substituted or unsubstituted C 1 -C 9 heterocyclic rings; or

viii) substituted or unsubstituted C 1 -C 9 heteroaryl rings;

L is a linking unit having the formula:

-[Q] y [C(R 5a R 5b )] x [Q 1 ] z [C(R 6a R 6b )] w —

Q and Q 1 are each independently:

i) —C(O)—;

ii) —NH—;

iii) —C(O)NH—;

iv) —NHC(O)—;

v) —NHC(O)NH—;

vi) —NHC(O)O—;

vii) —C(O)O—;

viii) —C(O)NHC(O)—;

ix) —O—;

x) —S—;

xi) —SO 2 —;

xii) —C(═NH)—;

xiii) —C(═NH)NH—;

xiv) —NHC(═NH)—; or

xv) —NHC(═NH)NH—;

R 5a and R 5b are each independently:

i) hydrogen;

ii) hydroxy;

iii) halogen;

iv) substituted or unsubstituted C 1 -C 6 linear or C 3 -C 6 branched alkyl; or

v) a unit having the formula:

—[C(R 7a R 7b )] t R 8

R 7a and R 7b are each independently:

i) hydrogen; or

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

R 8 is:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted C 6 or C 10 aryl;

iv) substituted or unsubstituted C 1 -C 9 heteroaryl; or

v) substituted or unsubstituted C 1 -C 9 heterocyclic;

R 6a and R 6b are each independently:

i) hydrogen; or

ii) C 1 -C 4 linear or C 3 -C 4 branched alkyl;

the index n is 0 or 1; the indices t, w, and x are each independently from 0 to 4; the indices y and z are each independently 0 or 1; or a pharmaceutically acceptable salt thereof.

175 . The method of claim 173 , wherein the ocular condition is glaucoma.

176 . The method of claim 173 , wherein the therapeutically-effective amount of the HPTP-β inhibitor is from about 0.5 mg to about 30 mg per treatment.

177 . The method of claim 173 , wherein the therapeutically-effective amount of the HPTP-β inhibitor is from about 15 mg per treatment.

178 . The method of claim 173 , wherein the anti-VEGF agent is ranibizumab.

179 . The method of claim 177 , wherein the therapeutically-effective amount of ranibizumab is about 0.05 mg to about 1.5 mg.

180 . The method of claim 173 , wherein the anti-VEGF agent is bevacizumab.

181 . The method of claim 179 , wherein the therapeutically-effective amount of bevacizumab is about 0.1 mg to about 5 mg.

182 . The method of claim 173 , wherein the anti-VEGF agent is aflibercept.

183 . The method of claim 181 , wherein the therapeutically-effective amount of aflibercept is about 0.05 mg to about 5 mg.

184 . The method of claim 173 , wherein the administering of the HPTP-β inhibitor is subcutaneous.

185 . The method of claim 173 , wherein the administering of the HPTP-β inhibitor is topical.

186 . The method of claim 173 , wherein the administering of the HPTP-β inhibitor is subcutaneous.

187 . The method of claim 173 , wherein the administering of the HPTP-β inhibitor is intravitreal.

188 . The method of claim 173 , wherein the administering of the HPTP-β inhibitor is subconjunctival.

189 . The method of claim 173 , wherein the administering of the HPTP-β inhibitor is to an eye of the subject.

190 . The method of claim 173 , wherein the HPTP-β inhibitor is formulated as a drop.

191 . The method of claim 173 , wherein the HPTP-β inhibitor is formulated as a drop, wherein the drop is administered to an eye of the subject.

192 . The method of claim 173 , wherein the administration reduces central foveal thickness in an eye of the subject.

193 . The method of claim 173 , wherein the subject is human.

194 . The method of claim 173 , wherein the administering of the anti-VEGF agent is intravitreal.

195 . The method of claim 173 , wherein the therapeutically-effective amount of the HPTP-3 inhibitor is from about 0.5 mg to about 30 mg per treatment, wherein the administering of the HPTP-β inhibitor is topical, wherein the HPTP-β inhibitor is formulated as a drop, wherein the therapeutically-effective amount of the anti-VEGF agent is about 0.05 mg to about 5 mg, and wherein the administering of the anti-VEGF agent is intravitreal.

196 . The method of claim 195 , wherein the ocular condition is glaucoma.